The deception-based threat detection in the BOTsink features decoys and lures that misdirect potential attackers from production assets. Through the collaboration, BOTsink decoys will provide software on certain BD products that will create mirror-match decoy authenticity. This will create an illusion where a potential attacker will not be able to tell what is real and fake. It will also show what an attacker is doing as they scan systems or try to download malware onto medical devices.
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.